Learning multiple sclerosis immunopathogenesis from anti-CD20 therapyFebruary 1, 2023·Michael Heming,Heinz Wiendl· 0 min read URL CitepublicationLast updated on April 17, 2023 ← Alemtuzumab treatment exemplifies discordant immune effects of blood and cerebrospinal fluid in multiple sclerosis. April 1, 2023Supporting the differential diagnosis of connective tissue diseases with neurological involvement by blood and cerebrospinal fluid flow cytometry February 1, 2023 →